CytomX Therapeutics (CTMX) vs Neurogene (NGNE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Neurogene (NGNE) has outperformed CytomX Therapeutics (CTMX) over the past year, gaining 10.2% versus a loss of 23.4%. Over five years, CTMX leads with a -50.4% price change compared with -82.1% for NGNE. CytomX Therapeutics is the larger company by market cap ($531.7 million vs $531.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTMX | NGNE |
|---|---|---|
| Share price | $2.44 | $26.56 |
| Market cap | $531.67M | $531.50M |
| 1-day change | -4.31% | +2.67% |
| YTD return | -40.14% | +25.58% |
| 1-year return | -23.42% | +10.23% |
| 5-year return | -50.39% | -82.08% |
| EPS (TTM) | $-0.51 | $-5.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.21 | $43.66 |
| 52-week low | $2.44 | $15.93 |
| Distance from 52-week high | -70.28% | -39.17% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +402.05% | +202.82% |
| Average volume | 3.34M | 245.99K |
| Shares outstanding | 217.90M | 20.01M |
| Employees | 69 | 131 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NGNE has outperformed CTMX by 33.6 percentage points over the past year.
About CytomX Therapeutics
CTMX stock →CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Neurogene
NGNE stock →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees
CTMX vs NGNE FAQ
Which is bigger, CytomX Therapeutics or Neurogene?
CytomX Therapeutics (CTMX) is larger, with a market capitalization of $531.67M compared with $531.50M for Neurogene (NGNE).
Which stock has performed better over the past year, CTMX or NGNE?
NGNE returned +10.23% over the past 12 months, compared with -23.42% for CTMX (price return, excluding dividends). Past performance does not predict future results.
Are CytomX Therapeutics and Neurogene in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.